Oncolytics Net Invested Capital from 2010 to 2024

ONCY Stock  USD 0.93  0.02  2.11%   
Oncolytics Biotech Net Invested Capital yearly trend continues to be fairly stable with very little volatility. Net Invested Capital will likely drop to about 20.3 M in 2024. Net Invested Capital is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. View All Fundamentals
 
Net Invested Capital  
First Reported
2010-12-31
Previous Quarter
27.6 M
Current Value
20.3 M
Quarterly Volatility
10.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Oncolytics Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncolytics Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 77 K, Interest Expense of 637.6 K or Selling General Administrative of 16.9 M, as well as many indicators such as Price To Sales Ratio of 66.83, Dividend Yield of 0.0 or PTB Ratio of 4.5. Oncolytics financial statements analysis is a perfect complement when working with Oncolytics Biotech Valuation or Volatility modules.
  
Check out the analysis of Oncolytics Biotech Correlation against competitors.
For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

Latest Oncolytics Biotech's Net Invested Capital Growth Pattern

Below is the plot of the Net Invested Capital of Oncolytics Biotech over the last few years. It is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. Oncolytics Biotech's Net Invested Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncolytics Biotech's overall financial position and show how it may be relating to other accounts over time.
Net Invested Capital10 Years Trend
Slightly volatile
   Net Invested Capital   
       Timeline  

Oncolytics Net Invested Capital Regression Statistics

Arithmetic Mean13,839,463
Coefficient Of Variation74.92
Mean Deviation8,804,853
Median8,283,846
Standard Deviation10,368,572
Sample Variance107.5T
Range36.2M
R-Value0.67
Mean Square Error64.3T
R-Squared0.44
Significance0.01
Slope1,545,685
Total Sum of Squares1505.1T

Oncolytics Net Invested Capital History

202420.3 M
202327.6 M
202226.5 M
202136.1 M
202024.8 M
2019-107.9 K
20186.2 M

About Oncolytics Biotech Financial Statements

Oncolytics Biotech investors use historical fundamental indicators, such as Oncolytics Biotech's Net Invested Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncolytics Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Invested Capital27.6 M20.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Oncolytics Stock Analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.